Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use …

Abstract

The present disclosure is directed to bispecific antibodies which bind to both PD-L1 and PD-L2, and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1, PD-L2, or both.